Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Abatacept

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Unknown2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05235438Phase 1Unknown

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

NCT05040256CompletedPrimary

Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency

NCT04377867Unknown

New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

Showing all 3 trials

Research Network

Common Treatments

  • Abatacept1
  • Imm27m1

Active Sponsors

  • The Scientific and Technological Research Council of Turkey1
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.1
  • University Hospital, Montpellier1
  • Marmara University1

Top Investigators

Related Conditions

  • Lrba Deficiency1
  • Oncology1

Activity Timeline